Oppenheimer Asset Management Inc. Ultragenyx Pharmaceutical Inc. Transaction History
Oppenheimer Asset Management Inc.
- $8.4 Billion
- Q2 2025
A detailed history of Oppenheimer Asset Management Inc. transactions in Ultragenyx Pharmaceutical Inc. stock. As of the latest transaction made, Oppenheimer Asset Management Inc. holds 6,514 shares of RARE stock, worth $224,081. This represents 0.0% of its overall portfolio holdings.
Number of Shares
6,514
Previous 7,140
8.77%
Holding current value
$224,081
Previous $258,000
8.53%
% of portfolio
0.0%
Previous 0.0%
Shares
28 transactions
Others Institutions Holding RARE
# of Institutions
364Shares Held
88.3MCall Options Held
3.64MPut Options Held
2.24M-
Vanguard Group Inc Valley Forge, PA10.2MShares$351 Million0.01% of portfolio
-
Black Rock Inc. New York, NY5.6MShares$193 Million0.01% of portfolio
-
Sands Capital Management, LLC Arlington, VA3.94MShares$136 Million0.43% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD2.89MShares$99.3 Million0.01% of portfolio
-
Baker Bros. Advisors LP New York, NY2.77MShares$95.4 Million1.02% of portfolio
About Ultragenyx Pharmaceutical Inc.
- Ticker RARE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 70,036,896
- Market Cap $2.41B
- Description
- Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast...